The FDA on May 6,2020 granted accelerated approval to TABRECTA® for adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have a mutation that leads to Mesenchymal-Epithelial Transition (MET) exon 14 skipping, as detected by an FDA-approved test. TABRECTA® is a product of Novartis.
Other Pages – Bottom Ad
Advertisement
Subscribe
